Gastroesophageal Reflux Disease (GERD) Clinical Trial
Official title:
Phase II Study of Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD
Objectives of the Study:
The primary objective of this study is to evaluate the relative merits, safety and
effectiveness of the tailored TIF2 procedure in treating GERD patients who have persistent
GERD symptoms despite PPI therapy.
The secondary objective of the study is to evaluate the effectiveness of the tailored TIF
procedure in restoring the antireflux barrier and eliminating GE reflux.
Type of Study:
Prospective, non-randomized, uncontrolled Study Duration 12 months Number of Patients 20
Inclusion Criteria:
Age 18-70 years, on daily PPIs for > 6 months, persistent GERD symptoms despite PPI therapy,
anatomic disruption of the gastroesophageal valve to a Hill Grade II-III, evidence of one of
the following while on PPI therapy: (1) erosive esophagitis (erosions or ulcerations during
endoscopy); (2) abnormal ambulatory pH study; or (3) biopsy confirmed changes characteristic
of reflux esophagitis; acceptable esophageal motility (by either manometry or video
esophagogram), hiatal hernia no larger than 2 cm, patient willing to cooperate with
post-operative dietary recommendations and assessment tests, signed informed consent
Exclusion Criteria:
BMI > 40, hiatal hernia > 2 cm, esophagitis grade D, esophageal ulcer, fixed esophageal
stricture, gastric motility disorders, previous splenectomy, pregnancy (female),
immunosuppression, ASA > 2, portal hypertension and/or varices, history of previous
resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum,
esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic
esophagitis, or cirrhosis, active gastro-duodenal ulcer disease, gastric outlet obstruction
or stenosis, gastroparesis or delayed gastric emptying, coagulation disorders
Interventions:
Treatment: Tailored transoral incisionless fundoplication (TIF2) using EsophyX system with
SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA)
Evaluation Criteria:
Primary Outcome Measure 24 hour pH impedance study: change in Johnson DeMeester scores;
GERD-HRQOL scores Secondary Outcome Measures PPI usage, GERD symptoms at 6 and 12 months vs.
baseline off PPI's, total number of reflux episodes, and Symptom Association Probability
while off PPI.
Safety: Adverse events will be mapped to standard terms and reported.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03561883 -
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
|
Phase 3 | |
| Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
| Completed |
NCT01406210 -
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol
|
N/A | |
| Terminated |
NCT01327963 -
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
|
N/A | |
| Completed |
NCT01570842 -
Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury
|
N/A | |
| Completed |
NCT02141711 -
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
|
Phase 1 | |
| Terminated |
NCT00587275 -
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
|
Phase 2 | |
| Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
| Completed |
NCT00261300 -
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
|
Phase 3 | |
| Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
| Completed |
NCT00795093 -
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
|
N/A | |
| Completed |
NCT00394472 -
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
|
Phase 2 | |
| Completed |
NCT00574925 -
Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients
|
Phase 4 | |
| Terminated |
NCT02749071 -
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux
|
N/A | |
| Recruiting |
NCT01129713 -
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
|
Phase 1/Phase 2 | |
| Completed |
NCT00734747 -
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
| Completed |
NCT00312806 -
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
|
Phase 3 | |
| Not yet recruiting |
NCT05579587 -
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
|
||
| Recruiting |
NCT02366169 -
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
|
N/A | |
| Completed |
NCT01374074 -
Racial Disparity in Barrett's Esophagus
|
N/A |